Denosumab (Prolia^®) for the treatment of osteoporosis in men at increased risk of fractures.

The National Osteoporosis Guideline Group (NOGG) clinical guideline for the prevention and treatment of osteoporosis (published September 2021) recommends the use of denosumab for the treatment of osteoporosis in men aged 50 years and over at increased risk of fracture as an option if first-line bisphosphonates are unsuitable or not tolerated. This national guidance endorses the routine use of this medicine for the same indication and specified patient cohort as the One Wales recommendation and as such, the One Wales advice is no longer required. In accordance therefore with the One Wales Medicines process, this advice has now been retired.

Availability of denosumab for this indication within NHS Wales will not be affected by the retirement of the One Wales recommendation.